- Featured News /
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
- Featured News /
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
- Featured News /
Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.
- Featured News /
Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.
- Featured News /
Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges
- Featured News /
Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.
- Featured News /
Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.
- Featured News /
RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.
- Featured News /
Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.
- Featured News /
For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.
Pagination
- ‹ Previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- …
- 20
- › Next page